ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
ANAPTYSBIO, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Operating margin
96.7%+128.6 pts over 5 years
Net margin
-5.6%+20.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +157.0% | +183.6% | +25.6% | +29.6% | |
| Operating income | +243.0% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.6% | -5.0% | -24.5% | |
| Return on assets | – | -4.7% | -3.1% | |
| Current ratio | 10.20 | 20.01 | 9.07 | |
| Interest coverage | -6.6× | – | – | |
| Capex to revenue | 0.3% | 0.8% | 0.0% | |
| Diluted shares | 3M | 27M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Anaptysbio generated $395.35M from operations and spent $122.06M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
Generated
$395.35M
Used
$122.06M
Capital expenditure$2.98M2%Dividends$00%Share buybacks$119.08M98%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-5.6%
×Asset turnover0.55×
×Equity multiplier7.85×
=Return on equity, FY2025-24.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -5.6% | 0.55× | 7.85× | -24.5% |
| FY2024 | -159.1% | 0.19× | 5.89× | -182.7% |
| FY2023 | -953.7% | 0.03× | 3.03× | -93.4% |
| FY2022 | -1251.3% | 0.02× | 2.03× | -41.6% |
| FY2021 | -91.5% | 0.12× | 1.41× | -15.3% |
| FY2020 | -26.6% | 0.18× | 1.06× | -5.0% |
| FY2019 | -1216.7% | 0.02× | 1.06× | -21.8% |
| FY2018 | -1233.1% | 0.01× | 1.06× | -15.5% |
| FY2017 | -300.7% | 0.05× | 1.45× | -22.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$13.23M
- Cash generatingOperating cash flow above zero$19.70M
- Return on assets improvedROA up on the prior year-32.1% → -2.7%
- Earnings backed by cashOperating cash flow above net income$19.70M vs -$13.23M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.51 → 9.07
- No dilutionShare count did not rise30M → 30M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.20 → 0.48